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The close integration of the MAPK, PI3K, and WNT signaling path-
ways underpins much of development and is deregulated in cancer. In
principle, combinatorial posttranslational modification of key lineage-
specific transcription factors would be an effective means to integrate
critical signaling events. Understanding how this might be achieved is
central to deciphering the impact of microenvironmental cues in
development and disease. The microphthalmia-associated transcrip-
tion factor MITF plays a crucial role in the development of melano-
cytes, the retinal pigment epithelium, osteoclasts, and mast cells and
acts as a lineage survival oncogene in melanoma. MITF coordinates
survival, differentiation, cell-cycle progression, cell migration, metab-
olism, and lysosome biogenesis. However, how the activity of this key
transcription factor is controlled remains poorly understood. Here, we
show that GSK3, downstream from both the PI3K andWnt pathways,
and BRAF/MAPK signaling converges to control MITF nuclear export.
Phosphorylation of the melanocyte MITF-M isoform in response to
BRAF/MAPK signaling primes for phosphorylation by GSK3, a kinase
inhibited by both PI3K and Wnt signaling. Dual phosphorylation, but
not monophosphorylation, then promotes MITF nuclear export by
activating a previously unrecognized hydrophobic export signal.
Nonmelanocyte MITF isoforms exhibit poor regulation by MAPK
signaling, but instead their export is controlled by mTOR. We un-
cover here an unanticipated mode of MITF regulation that inte-
grates the output of key developmental and cancer-associated
signaling pathways to gate MITF flux through the import–export
cycle. The results have significant implications for our understand-
ing of melanoma progression and stem cell renewal.
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The ability of transcription factors to respond to distinct signaltransduction pathways and thereby implement gene expres-
sion programs characteristic of specific cell identities underpins
development and is deregulated in disease. However, the output
of discrete signaling modules should be integrated if complex
microenvironmental cues are to be coordinated with cell be-
havior and the adoption of particular phenotypic states. This
implies that those transcription factors with a key role in co-
ordinating many aspects of cell biology may act as a nexus for
multiple signaling pathways, integrating their output to fine-tune
the expression of specific repertoires of target genes. Identifying
how such master regulators of cell phenotype respond and co-
ordinate multiple signaling inputs is key to deciphering the im-
pact of signaling in development and disease.
The MITF gene encoding the microphthalmia-associated
transcription factor not only determines cell identity in devel-
opment but resides at the heart of melanocyte and melanoma
biology where it coordinates a remarkably wide range of cell
functions. MITF is a lineage survival oncogene (1) that cooperates
with BRAF in melanoma initiation (2). It is required for mela-
noblast (3) and melanoma (4) survival and differentiation (5) but
inhibits invasiveness (6) and tumor-initiation capacity (7). MITF
has both a positive and negative role in cell division, promoting a
differentiation-associated cell-cycle arrest (5) but also driving
proliferation (6, 8). The positive and negative roles in melanoma
and melanocyte proliferation have been explained by the so-called
rheostat model for MITF function, in which its expression and
activity increase as cells progress from invasiveness, through pro-
liferation to differentiation (6, 9). Consistent with this, MITF is
repressed by stresses that reprogram translation and drive invasion
and drug and immunotherapy resistance (10). This model appears
broadly to explain the correlations between MITF expression and
invasive and proliferative phenotypes in melanoma. In addition,
both low and high MITF have been associated with drug re-
sistance (11–14), and siRNA-mediated depletion of MITF in
melanoma triggers senescence (15). MITF has also been implicated
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in the biogenesis of both lysosomes (16, 17) and mitochondria (18,
19), thereby contributing to both autophagy and metabolism. Beyond
melanocytes and melanoma, MITF is transcribed from alternative
promoters generating isoforms with distinct first exons (20). These
alternative isoforms promote differentiation of the retinal epithe-
lium, osteoclasts, and mast cells (3) and recently have been impli-
cated in the proliferation of pancreatic ductal adenocarcinoma (21).
Given the critical role of MITF in so many aspects of de-
velopmental and cancer biology, understanding whether and how
it might integrate the output from the complex microenviron-
mental cues encountered by cells in development or in tumors is
a key issue. Several posttranslational modifications of MITF
have been identified to date, but the role of many is poorly un-
derstood. MITF is sumoylated at two sites, K182 and K316
(22–25), which is thought to promote differential target
specificity. Importantly the MITF E318K mutation that pre-
vents sumoylation on K316 predisposes to melanoma (24, 25),
confirming the prooncogenic role of MITF. In addition to
sumoylation, MITF is modified by several kinases. These include
the mitogen-activated protein kinase (MAPK) ERK2 and RSK,
with ERK-mediated phosphorylation on S73 reported to mediate
increased binding to the p300 and CBP transcription cofactors (26),
as well as ubiquitin-mediated degradation (27, 28). In osteoclasts,
the stress-activated kinase p38 phosphorylates MITF on S307 to
facilitate activation of gene expression (29) whereas phosphory-
lation of nonmelanocyte isoforms by TAK1 (30) or mTOR (31)
mediates cytoplasmic retention via binding to a 14-3-3 protein.
Whether p38, TAK1, and mTOR are MITF kinases in melanocytes/
melanoma is unknown. GSK3, which is inhibited by both PI3K and
Wnt signaling, has been reported to modify S298 to influence DNA
binding (32), and more recently three C-terminal GSK3 sites have
been implicated in controlling MITF protein stability (17). Whether
and how other signals control MITF activity through posttransla-
tional modification are unknown.
Here, we reveal that critical developmental signaling pathways
already known to promote tumor initiation and senescence bypass
in melanoma converge to control an ERK- and GSK3-regulated
MITF nuclear export signal that regulates flux through the nuclear
import–export cycle.
Results
In different tissues and cell types, MITF expression is controlled by
distinct promoters, leading to the inclusion of different exons at the
N terminus of the protein (20). In neural crest-derived melanocytes
and melanoma, the MITF-M isoform predominates and is referred
to here as MITF. Although many groups have focused on how
changing MITF levels affect its function, the activity of MITF will
also be influenced by its posttranslational modifications. However,
despite several posttranslational modifications on MITF being
identified (Fig. 1A), few have been assigned a clear regulatory
function. Posttranslational modifications can potentially control
transcription factor levels, interaction with cofactors, intramolecular
conformation, DNA-binding affinity, or intracellular localization.
To identify additional kinases that might affect MITF expression
or subcellular localization, we undertook a phenotypic screen of
SKmel28 human melanoma cells using a 367 compound small
molecule kinase inhibitor library (33). Cells were treated with 2.5 μM
of each compound and examined 6 h later using an anti-MITF an-
tibody for immunofluorescence. The ratio of nuclear to cytoplasmic
staining and the mean intensity of nuclear MITF were normalized
relative to a corresponding DMSO-treated internal control. The
preliminary results indicated that compounds targeting GSK3 (SI
Appendix, Fig. S1A) promoted increased MITF nuclear accumula-
tion at the expense of weak cytoplasmic staining that was re-
producibly observed using different MITF antibodies. As an
example, BIO, a selective, ATP-competitive inhibitor of GSK3 (34)
increased MITF nuclear localization (Fig. 1B). β-catenin, which is
degraded in response to GSK3-mediated phosphorylation, was used
as a control. Similar results were obtained using SB-675259-M, a
chemically distinct GSK3 inhibitor (SI Appendix, Fig. S1B). GSK3 is
important as it is inhibited by PI3K signaling that is frequently ac-
tivated in melanoma either through PTEN loss or via activating
mutations in the PI3K catalytic subunit (35). In melanoma, PI3K
signaling inhibits GSK3 activity and promotes resistance to anti-
BRAF inhibitor therapies (36) and senescence bypass (37).
GSK3 is also inhibited by WNT signaling that stabilizes β-catenin
that can also promote senescence bypass in melanoma (38). Con-
sistent with GSK3 targeting MITF, both the GSK3 inhibitor BIO
or the structurally distinct GSK3 inhibitor SB-675259-M caused
MITF to migrate at an intermediate position between the known
hypophosphorylated lower form and the upper band that is known to
be phosphorylated on S73 by ERK (39) when analyzed by SDS/
PAGE and Western blotting (Fig. 1C).
One interpretation of these data is that phosphorylation by ERK
on S73 promotes phosphorylation by GSK3 on another residue. As
such, mutation of S73 would prevent phosphorylation by both kinases,
but GSK3 inhibition would not affect phosphorylation by ERK. This
model is attractive since GSK3 frequently requires a priming phos-
phorylation site; the consensus recognition motif for GSK3 is S-X-X-
X-pS, with the first serine being phosphorylated by GSK3 after a
priming phosphorylation on the serine at the +4 position (40).
Examination of the MITF amino acid sequence in the vicinity of
S73 revealed a potential GSK3 phosphorylation site at S69 that
was evolutionarily conserved from zebrafish to humans (Fig. 1D).
Moreover, a large-scale phosphoproteome analysis previously identi-
fied both S69 and S73 as being phosphorylated (41) although the
nature of the relevant kinases and implications of phosphorylation
were not examined. In this respect, the spacing between the ERK
phosphorylation site at S73 and the GSK3 site at S69 matched the
consensus and implied that ERK would act as the priming kinase.
This was confirmed using an in vitro kinase assay on a series of
WT and mutated MITF peptides spanning S69 and S73 (Fig.
1E). Only peptide 6 containing an intact S69 as well as p-S73 was
phosphorylated by purified GSK3β. A peptide (peptide 7) con-
taining a substitution of S73 by a glutamic acid, frequently used
to mimic phosphorylation, was not phosphorylated by GSK3β,
highlighting the specificity of the S73 phosphorylation event in
priming for GSK3β.
The results obtained using the peptide kinase assay were con-
firmed using a quantitative Mass Spec (MS) approach, in which
the bacterially expressed and purified N-terminal domain of
MITF (SI Appendix, Fig. S2A) was subject to phosphorylation in
vitro using ERK and GSK3β alone or together (SI Appendix, Fig.
S2 B–E). Quantification (SI Appendix, Fig. S2F) revealed that,
while ERK phosphorylated S73 but not S69, the modification of
S69 by GSK3β was inefficient unless S73 was phosphorylated.
Western blotting of extracts from cells expressing WT and
mutant MITF further substantiated our conclusion that phos-
phorylation of S73 primes for GSK3-mediated phosphorylation at
S69. Mutation of S69 led to MITF adopting an intermediate
mobility (Fig. 1F), similar to that observed using GSK3 inhibitors
(Fig. 1C), whereas mutation of S73, as predicted, led to a complete
shift to the lower position. No effect on MITF mobility was de-
tected after mutation of S298 that has previously been reported as
a GSK3 target (32). Both the upper and lower bands were shifted
down if the three C-terminal GSK3 sites identified by Ploper et al.
(17) were mutated although the ratio between the upper and lower
bands was maintained and no substantial effect on protein levels
was observed. Phosphatase treatment of extracts from 501mel cells
transfected with FLAG-tagged WT and mutant MITF followed by
Western blotting led to increased mobility of MITF to a position
below that of the S73A mutant (Fig. 1G). This result is consistent
with MITF being phosphorylated on multiple residues in addition
to S73 and S69, including the C-terminal GSK3 phosphorylation
sites. Note that the charge on the glutamic acid substitution mu-
tants results in a small reduction in protein mobility.


























































Fig. 1. GSK3 phosphorylates MITF S69 to control MITF subcellular localization. (A) MITF posttranslational modifications. (B) Immunofluorescence of
SKmel28 cells following treatment with 1 μM BIO or DMSO for 18 h. Cells were stained with DAPI (blue) and antibodies against MITF (green) or β-catenin (red).
Quantification (Right). n > 70 per condition. Error bars represent SEM. Two-tailed t test: ****P < 0.0001. (C) Western blot of SKmel28 cells following
treatment with 1 μM BIO, 1 μM of SB-675259-M, or DMSO as in A. (D) Amino acid sequence alignment of MITF. In the GSK3 consensus, X = any amino acid. (E,
Left) Twenty-one residue peptides corresponding to MITF amino acids 61 to 81 used for the SPOT kinase assay immobilized on a cellulose support membrane.
(E, Right) SPOT kinase assay using purified GSK3β. A map showing the identity of the 10 tested peptides (Left) corresponding to peptide spots on the
membrane imaged in UV light (Middle), and the kinase assay (Right). (F) Western blot of 501mel cells ectopically expressing indicated MITF-FLAG WT and
mutants. (G) Western blot of extracts from 501mel cells ectopically expressing indicated MITF-FLAG WT and mutants treated or not with calf intestinal
phosphatase (CIAP). (H and I) Fluorescence images of 501mel cells ectopically expressing GFP-MITF WT and indicated mutants (green). (Scale bars: 10 μm.)
Quantification (Right). n > 40 per condition. Error bars represent SEM. Two-tailed t test (Upper) and one-way ANOVA with post hoc Tukey test: ****P <
0.0001, NS, not significant, P > 0.05. (J) Luciferase assay with MITF-FLAGWT and mutants and a TYR promoter-Luc reporter cotransfected into HeLa cells. Error
bars represent SEM. Two-tailed t test: ****P < 0.0001. Western blot shows relative expression of WT and mutant MITF-FLAG proteins.



















































Using an MITF–GFP fusion protein expressed in MITF-negative
HeLa cells confirmed that the cytoplasmic fluorescence detected
using the WT protein was abolished by either the S69A or S73A
mutations whereas mutating either S298 or the C-terminal GSK3
sites had no effect on MITF localization (Fig. 1H). Moreover, in-
troduction of phosphomimetic glutamic acid substitutions at S69 or
at both S69 and S73 gave a similar pattern of cytoplasmic MITF
localization as the WT (Fig. 1I) while the S69A and S69A, S73A
mutants were significantly more nuclear. Note that the S69E mutant
was significantly more cytoplasmic than the S69Amutant, suggesting
that S69 may control subcellular localization. Moreover, the in-
creased nuclear localization of the S69A and S73A mutants was
reflected in their increased capacity to activate a Tyrosinase-
promoter-luciferase reporter (Fig. 1J).
Cytoplasmic Accumulation of MITF in Response to BRAF/MAPK
Signaling. To examine the impact of regulating MAPK signaling
on MITF subcellular localization, we treated 501mel melanoma
cells with 12-O-tetradecanoylphorbol-13-acetate (TPA). TPA effi-
ciently promoted ERK phosphorylation and a mobility shift in
MITF consistent with increased phosphorylation on S73, with both
being blocked by the MEK inhibitor U0126 (Fig. 2A). As antici-
pated, given the role of S73 phosphorylation in priming GSK3-
mediated modification of S69, TPA increased nuclear localization
of activated ERK and the proportion of cytoplasmic MITF, an
effect blocked using U0126 (Fig. 2B). MITF cytoplasmic accumu-
lation in response to TPA was prevented using the GSK3 inhibitor
BIO (Fig. 2C), as well as by the S73A mutation, and was reduced
using the S69A mutant (Fig. 2D), indicating that phosphorylation
on S73 in the absence of S69 phosphorylation can make a contri-
bution to MITF’s subcellular localization independently of its
ability to promote S69 phosphorylation. Similar results were
obtained in HeLa cells where induction of doxycycline-inducible
BRAFV600E promoted cytoplasmic localization of WT MITF-
GFP (Fig. 2E), which was blocked using U0126, but did not trig-
ger cytoplasmic accumulation of the S73A mutant.
MITF Contains a BRAF/MAPK-Regulated Nuclear Export Signal. Although
TPA induced MITF to be completely phosphorylated at S69 and
S73 (Fig. 2A), TPA did not induce all endogenous MITF to be lo-
calized to the cytoplasm (Fig. 2B). The balance between cytoplasmic
and nuclear localization will be influenced by several factors, in-
cluding the relative rate of nuclear import and export. MITF’s nu-
clear import is mediated by a constitutive nuclear localization signal
in the basic region of the bHLH-LZ domain (42). Whether MITF is
subject to active nuclear export is not known. Preliminary evidence
indicated that the N-terminal region of MITF (residues 1 to 180)
could relocalize to the cytoplasm in response to TPA treatment (SI
Appendix, Fig. S3A). Moreover, a series of N-terminal deletion
mutants revealed that TPA was able to promote cytoplasmic lo-
calization of MITF lacking the N-terminal 60 amino acids but was
unable to do so if an additional 40 amino acids were removed (SI
Appendix, Fig. S3B). Thus, residues 60 to 100, which contain the
S69 and S73 regulatory phosphorylation sites, were required for
TPA-induced cytoplasmic localization. Examining the amino acid
sequence in the vicinity of S73, the key regulator of MITF cyto-
plasmic accumulation, revealed a hydrophobic patch (MxMLxL)
that resembled a classical nuclear export signal (NES) (43)
Fig. 2. BRAF/MAPK signaling redirects MITF to the
cytoplasm. (A) Western blot or (B) immunofluores-
cence of 501mel cells following 200 nM TPA treat-
ment (1 h) in the presence or absence of 10 μM
U0126 (3 h). After fixation and permeabilization, the
cells were stained with the nucleic acid stain DAPI
(blue) and antibodies against MITF (green) or
phospho-ERK (red). n >100 for each condition. (C)
Immunofluorescence of 501mel cells treated with
200 nM TPA (1 h) and/or 1 μM BIO. n > 40 cells per
condition. (D) Fluorescence assay of 501mel cells ec-
topically expressing WT or mutant MITF-GFP and
treated with 200 nM TPA for 1 h as indicated. n >
49 for each condition. (E) Immunofluorescence of
Flip-in HeLa cells engineered to express doxycycline-
inducible BRAFV600E-FLAG ectopically expressing
GFP-MITF WT or the S73A mutant (green). Twenty-
four hours posttransfection, cells were treated with
2 ng/mL doxycycline for 24 h and treated as in-
dicated with 10 μM U0126 for 3 h. Anti-FLAG-BRAF
(red). n > 10 cells per condition. Quantification by
two-tailed t test or one-way ANOVA with post hoc
Tukey test (E):*P < 0.05; **P < 0.01; ***P < 0.001;
****P < 0.0001; NS, not significant, P > 0.05; error
bars represent SEM.


























































(Fig. 3A). We confirmed that MITF is subject to active export from
the nucleus using leptomycin B (LMB), an inhibitor of chromosome
maintenance 1 (CRM1)-mediated export (44), which increased
nuclear localization of MITF (Fig. 3B) and prevented cytoplasmic
accumulation of MITF-GFP in response to TPA treatment (Fig.
3C). Consistent with these observations, MITF was able to directly
interact with CRM1 in a RAN-GTP–dependent fashion in vitro
using bacterially expressed and purified proteins (Fig. 3D), consis-
tent with results from a previous deep proteomic assay for CRM1
interactions (45).
To determine whether this region of MITF contains a func-
tional NES, we used a GFP-based fluorescent NES reporter
vector. Since the final size of any GFP fusion protein in the re-
porter needed to be greater than 40 kDa to prevent passive
diffusion between the cytoplasm and nucleus (46), GST was
fused in frame with GFP. The parental GFP-GST reporter was
largely cytoplasmic (SI Appendix, Fig. S4A). The addition of a
nuclear localization signal (NLS), PKKKRKV, from the simian
virus 40 (SV40) T-antigen (47), led to the reporter being
expressed in the nucleus. Further addition of a classical NES,
LALKLAGLDI, from the cAMP-dependent protein kinase in-
hibitor (PKI) (48) served as a positive control for nuclear export,
relocalizing the NLS-containing reporter protein to the cyto-
plasm. TPA had no effect on the localization of any of these
proteins. Replacement of the PKI NES with MITF amino acids
60 to 99 led to the reporter being distributed between the nu-
cleus and cytoplasm (Fig. 3E), but addition of TPA promoted
cytoplasmic localization. Consistent with our previous observa-
tions, the S73A mutant was unresponsive to TPA and was lo-
calized primarily to the nucleus whereas the S69A mutant largely
abrogated the increased cytoplasmic localization triggered by
TPA. Importantly, the MEK inhibitor U0126 significantly re-
duced the cytoplasmic localization induced by TPA while the
reporter was almost completely localized in the nucleus in the
presence of LMB, irrespective of the presence or absence of
TPA (Fig. 3F). Collectively, these data are consistent with MITF
containing a MAPK and GSK3 coregulated NES.
To characterize better the requirements for MITF nuclear
export, we used the same GFP-NLS-GST reporter to analyze the
effect of mutations in the putative hydrophobic NES. Single al-
anine substitutions in M75, L78, and L80 all abrogated the
relocalization to the cytoplasm in response to TPA (SI Appendix,
Fig. S4B). By contrast, mutation of M77 had no effect. The role
of M75, L78, and L80 in nuclear export was confirmed in the
context of full-length MITF where the relocalization of the WT
protein to the cytoplasm in response to TPA was prevented by
alanine substitution in any of these three residues (SI Appendix,
Fig. S4C). Importantly, mutation of L75, L78, or L80 did not
affect the ERK-mediated mobility shift in MITF in response to
TPA arising via phosphorylation of S73 (SI Appendix, Fig. S4D).
Regulation of Nonmelanocyte Isoforms. The results so far suggest
that phosphorylation of MITF on S73 by ERK downstream from
BRAF triggers GSK3-mediated phosphorylation of S69 and,
consequently, NES-mediated MITF nuclear export. In mela-
noma cells, activation of this pathway, by induction of MAPK
activity in response to TPA or BRAF for example, leads to an
increased proportion of MITF relocalizing to the cytoplasm.
However, under standard growth conditions, only 10 to 20% of
endogenous MITF is cytoplasmic, most likely reflecting the fact
Fig. 3. MITF has a nuclear export signal. (A) Align-
ment of MITF sequences in the vicinity of S69 and
S73 from different species. Hydrophobic residues
highlighted in blue indicate the putative NES. (B)
Immunofluorescence of endogenous MITF in 501mel
cells treated with 20 nM LMB for 3 h as indicated. n >
80 cells per condition. (C) Fluorescence images of
501mel cells ectopically expressing WT GFP-MITF
(green) treated with 200 nM TPA for 1 h and/or
20 nM LMB for 3 h. n > 49 per condition. (D) CRM1
pull-down assay using bacterially expressed HIS-
Tagged MITF (1–105) bound to Ni-NTA beads. All
proteins were bacterially expressed and purified,
and, after pull-down, CRM1 and RAN were detected
by Western blotting using specific antibodies. Puri-
fied MITF was visualized by Coomassie staining
(Lower). (E and F) Fluorescence assay of 501mel cells
transfected with indicated GFP reporters. n > 43 per
condition. Quantification by two-tailed t test: **P <
0.01; ****P < 0.0001; NS, not significant, P > 0.05;
error bars represent SEM.



















































that nuclear import is efficient and that the melanocyte-specific
isoform of MITF, MITF-M, is not retained in the cytoplasm. By
contrast, other isoforms of MITF bearing different first exons
arising from differential promoter usage (20) can localize to the
cytoplasm more completely owing to cytoplasmic retention fol-
lowing phosphorylation of S173 by TAK1 in osteoclasts (30), or
by phosphorylation by mTORC1 and the interaction with the
RAG GTPases at the surface of the lysosome (31). We therefore
examined the impact of inhibiting nuclear export of the MITF-A
and MITF-D isoforms. In both cases, transfection of HeLa cells
with MITF-A or MITF–D expression vectors led to a largely
cytoplasmic localization (Fig. 4A and SI Appendix, Fig. S5A).
Cytoplasmic retention of the nonmelanocyte isoform MITF-A
was prevented by mutation of conserved residues Q62 and
L63 within exon B1b (SI Appendix, Fig. S5B) that is required for
interaction with the RAG GTPases (31), and by Torin 1 (SI
Appendix, Fig. S4A), an inhibitor of mTOR that phosphorylates
on an MITF-M S173-equivalent residue to promote cytoplasmic
retention via phosphorylation-mediated 14-3-3 binding.
However, in both MITF-A and MITF-D, nuclear export is also
important since treatment with either LMB or the GSK3 inhibitor
BIO led to increased accumulation of MITF-A or MITF-D within
the nucleus (Fig. 4A and SI Appendix, Fig. S5A). Moreover, intro-
ducing the MITF-M L80A equivalent into the MITF-A andMITF-D
isoforms also substantially increased nuclear retention of each iso-
form. Inhibition of MEK, using U0126 to reduce MAPK activity,
also increased MITF-A and -D nuclear localization to a similar
extent as BIO, but less than Torin 1, indicating that ERK-mediated
phosphorylation of MITF makes a previously unrecognized con-
tribution to the subcellular localization of nonmelanocyte isoforms.
These observations were confirmed by examining endogenous
MITF in both retinal pigment epithelia (RPE) ARPE19 cells,
which express multiple nonmelanocyte MITF isoforms (20), and
osteoclasts, which express both the MITF-A and -D isoforms
(49). LMB promoted dramatically increased nuclear localization
of MITF in the ARPE19 RPE cell line (Fig. 4B), and, in osteo-
clasts, MITF nuclear accumulation was also increased in re-
sponse to BIO, U0126, Torin 1, and LMB (SI Appendix, Fig.
S5C). The results obtained using LMB reveal that regulated
nuclear export plays a key role in controlling the nuclear avail-
ability of endogenous MITF in these cells. These data indicate
that the nuclear export signal is highly active in different MITF
isoforms. The reason the endogenous MITF-M isoform does not
more efficiently accumulate in the cytoplasm under steady-state
conditions is most likely the absence of alternative exon 1B1b
since mutation of the RAG GTPase interaction motif generated
predominantly nuclear MITF-A (SI Appendix, Fig. S5B).
MITF S69 Is Critical for Melanocyte Development. To investigate the
possibility that S69 was important in melanocyte development, we
mutated the equivalent of the S69 residue in zebrafish Mitfa to al-
anine, which prevents phosphorylation, or glutamic acid, which can
mimic constitutive phosphorylation. We then injected plasmids
encoding these mutants under the control of the fish Mitfa promoter
into mitfa-null nacre zebrafish embryos and determined if the mu-
tants could rescue melanophore development in these embryos. The
results (Fig. 5) revealed that the S69A mutant could rescue mela-
nophore development (number of embryos = 29, mean number of
melanophores per embryo = 6.1), as did WT Mitfa (n = 11, mean =
9.9). Although there were fewer melanophores per embryo with the
S69A mutant compared with the WT, there were no significant
differences between the WT and mutant variants as determined by
one-way ANOVA test [95%CI: (−0.876, 8.418)]. On the other hand,
the phosphomimetic S69E mutant, that exhibits significantly in-
creased cytoplasmic localization compared with S69A (Fig. 1I), failed
to rescue melanophore development in all injected embryos (n = 26,
mean = 0). WT and mutant Mitfa were similarly expressed in mitfa-
null zebrafish embryos (SI Appendix, Fig. S6). However, while there
is a clear difference in the ability of the S69A and S69E mutants to
complement the lack of MITF in zebrafish consistent with the
phosphorylation status of S69 in MITF being critical for melanocyte
development, the absence of antibodies able to recognize MITF or
phospho-S69 in fish means that the role of S69 phosphorylation in
MITF nuclear export in this model requires further validation.
Discussion
Many nuclear export signals have been characterized (43), and
some, like the yeast transcription factor Pho4 (50) or cyclinD1
(51), are regulated by phosphorylation. However, the NES in
MITF is highly unusual in the sense that it acts as a nexus for key
developmental signaling pathways implicated in melanoma ini-
tiation and progression (Fig. 6). In the melanocyte-specific
MITF isoform, MITF-M, phosphorylation of S73 by ERK
downstream from BRAF and NRAS primes for phosphorylation
of S69 by GSK3.
Under standard culture conditions, GSK3 is active, and, con-
sequently, it is the priming activity of ERK that dictates whether
the MITF NES operates. Despite the melanoma cells used here
having a BRAFV600E mutation, ERK activity is not maximal and can
be stimulated by TPA, leading to increased cytoplasmic localiza-
tion of MITF-M. However, GSK3 activity can be suppressed by
PI3K signaling that is frequently activated in melanoma: for ex-
ample, by loss of PTEN. Since both ERK- and GSK3-mediated
phosphorylation events are necessary for efficient export to oc-
cur, the MITF export signal potentially provides a route to inte-
grate MAPK and PI3K signaling with regulation of MITF’s target
genes implicated in both proliferation and differentiation. Mech-
anistically, we view it likely that the hydrophobic MITF nuclear
export signal may be occluded by an intramolecular interaction
and that the phosphorylation events alter the conformation to un-
mask the export signal. In this scenario, a single phosphorylation
event on S73 may contribute, but the dual phosphorylation on
S73 and S69 will be more efficient, as in fact we observed.
Although the level of endogenous MITF-M observed in the
cytoplasm is relatively low in melanoma cells in culture, the
steady-state ratio of nuclear to cytoplasmic MITF is likely to be
less important than flux through the import–export cycle. For
any transcription factor, nuclear localization is necessary for it to
find its target genes. The probability of its being able to do so will
Fig. 4. Regulated nuclear export of MITF-A isoforms. (A) Immunofluores-
cence using anti-MITF antibody of HeLa cells transfected with expression
vectors for MITF-A isoform treated with indicated drugs (20 nM LMB; 10 μM
U0126; 200 nM Torin 1; 1 μM BIO) or expressing the L80A mutant. n > 20 cells
per condition. (B) Immunofluorescence using anti-MITF of ARP19 (RPE) cells
with or without 20 nM LMB. n > 20 cells per condition. (Scale bars: 10 μm.)
Quantifications by two-tailed t test: **P < 0.01; ***P < 0.001; ****P <
0.0001. Error bars represent SEM.


























































depend on its residence time in the nucleus. Activation of the
MITF NES will lead to decreased nuclear residence time and is
therefore likely to diminish the ability of MITF to bind and
regulate its targets. As such, even a 10% increase in the cytoplasmic
localization may in reality reflect a far greater effect on productive
MITF DNA-binding and gene regulation. Moreover, phosphory-
lation of S73 by ERK has been reported to promote proteasome-
mediated degradation of MITF (27, 28) although we have not
detected any increased expression of an S73A mutant versus the
WT protein. Nevertheless, the role of S73 phosphorylation in
stimulating export raises the possibility that export may enhance
cytoplasmic MITF turnover, and, consequently, the levels of steady
state cytoplasmic MITF may be underestimated.
In contrast to MITF-M, where the majority of the protein is
nuclear under standard culture conditions, the nonmelanocyte
MITF isoforms that are critically required for development of mast
cells, osteoclasts, and the RPE are predominantly cytoplasmic. Since
inhibition of the NES using LMB promotes localization of MITF-A
and -D to the nucleus, it seems that the nonmelanocyte isoforms are
constantly passing through the import–export cycle, with their pre-
dominantly cytoplasmic localization arising as a result of cytoplasmic
retention. This occurs because the nonmelanocyte MITF isoforms,
but not MITF-M, contain residues within their N-terminal region
that mediate binding to RAG GTPases at the lysosomal surface
where they can be phosphorylated by the nutrient sensing mTORC1
complex (31). Phosphorylation of nonmelanocyte isoforms by
mTORC1 at S173 (using MITF-M numbering) will lead to cyto-
plasmic retention by promoting interaction with a 14-3-3 protein
(30). Consequently, inhibition of mTOR using Torin 1 or mutation
of the RAG-interacting region leads to their nuclear accumulation.
Since inactivation of mTORC1 via nutrient limitation will lead to
nuclear accumulation of the nonmelanocyte isoforms (31), the NES
identified here will play a key role in restoring cytoplasmic MITF
localization when nutrient levels are restored. However, the bi-
ological reason why the melanocyte-specific MITF-M isoform is not
regulated by mTOR remains unclear. One possibility is that, during
melanoblast migration, mTOR-mediated MITF export and cyto-
plasmic retention would be incompatible with regulation of MITF-
driven melanoblast proliferation, and, consequently, MITF-M needs
to be uniquely perceptive to MAPK signaling.
Although, for technical reasons, we have been unable to
measure MITF phosphorylation in the fish model, an S69E
substitution in Mitfa prevents melanocyte development whereas
an S69A mutation complements MITF loss efficiently. These
observations suggest that the phosphorylation status of S69 may
be important during melanocyte development. We also envisage
there may be two additional scenarios where a regulated MITF-
M export signal may be important.
First, activation of BRAF or NRAS by mutation in primary
melanocytes in vivo would trigger an instantaneous increase in
MAPK signaling and consequently decrease MITF nuclear lo-
calization by promoting export. Since, in primary melanocytes,
activating mutations in BRAF or NRAS trigger senescence, it is
possible that the downstream activation of MAPK signaling
would increase MITF export, as we observed following induction
of BRAFV600E expression, thereby preventing MITF driving pro-
liferation. Since depletion of MITF in cells bearing activated
BRAF triggers senescence (15), these observations are consistent
with a model in which an active MITF NESmight pose a barrier to
BRAF-mediated melanoma initiation in vivo. Additional muta-
tions in signaling pathways leading to inactivation of GSK3 would
prevent MITF export and, consequently, complement BRAF ac-
tivation by enabling MITF to remain nuclear to stimulate pro-
liferation. Consistent with this scenario, PI3K (37) and WNT
signaling (38) both inhibit GSK3 and are implicated in senescence
bypass in melanoma (52–54). We also note that GSK3 can be
inhibited by phosphorylation by p90 RSK lying downstream from
ERK and BRAF (55). Although we have not examined the impact
of BRAF activation on GSK3 activity, the possibility that BRAF
activation can lead to inhibition of GSK3 suggests that the MITF
export signal may be also be modulated by the kinetics of RSK
activation in response to different upstream signals.
Secondly, while the MITF-M NES might provide a mechanism
to protect against cancer initiation, its primary purpose will be to
regulate MITF activity under physiological conditions. WNT
signaling increases MITF-M protein stability by preventing
phosphorylation of the C-terminal GSK3 sites (17) and also in-
creases MITF-M mRNA expression via β-catenin–mediated ac-
tivation of the MITF-M promoter (56), an event that commits
cells to a melanocyte lineage fate to generate melanoblasts (57).
Our results suggest that inhibition of GSK3 by WNT might also
promote MITF activity by preventing MITF nuclear export.
Moreover, WNT-mediated activation of melanocyte stem cells in
the hair follicle bulge (58) should drive proliferation by both
increasing MITF expression and preventing MITF export. We
also note that a point source of WNT can promote cell division
Fig. 5. MITF S69 is required for melanocyte development. (A) Representa-
tive images of mitfa-null nacre embryos injected with plasmids encoding
Mitfa WT or indicated mutants taken 5 d postfertilization (dpf). (B) Quan-
tification of the number of rescued melanocytes per embryo. Mitfa WT
(number of embryos n = 11, mean melanocytes per embryo = 9.9); S69A
mutant (number of embryos = 29, mean number of melanocytes per
embryo = 6.1); S69E number of embryos = 25, mean = 0). For WT vs. S69A:
no significant difference by one-way ANOVA test [95% CI: (−0.876,
8.418)] (experimental replicates n = 3).
Fig. 6. Model illustrating potential regulation of MITF nuclear export.



















































in the plane of the WNT signal (59), giving rise to two daughter
cells, with either high WNT signaling and consequently low
GSK3 activity close to the source, or low WNT signaling and
high GSK3 in the daughter cell furthest from the source. In
principle, this would create two daughter cells with differential
activity of the MITF export signal. If point source WNT signaling
occurs in the melanocyte stem cell niche, the regulated export
signal has the potential to decrease MITF activity in the distal
daughter cell, an event that would facilitate stem cell renewal.
While this model is speculative, it does provide a framework for
studies that would investigate the potential role of the MITF
export signal in stem cell renewal.
While we confirmed that MITF is phosphorylated by GSK3 at
its C terminus as described previously (17), we saw no effect of
mutating the reported (32) S298 GSK3 phosphorylation site on
MITF subcellular localization or mobility by SDS/PAGE.
Moreover, this site is not localized near any putative priming
phosphorylation site that is usually required for GSK3-mediated
phosphorylation. Given that S298 lies at the end of the MITF
leucine zipper and is not able to mediate DNA contact (60), it is
difficult to understand mechanistically how it can affect DNA
recognition as reported (32). Moreover, in a separate study, Grill
et al. (61) showed that the S298A mutation did not have any
significant effect on MITF’s ability to bind DNA or transactivate
the TYR promoter, as well as other downstream targets such as
the TYRP1 and DCT promoters. We therefore feel it unlikely
that S298 represents a bona fide GSK3 phosphorylation site.
Materials and Methods
Cell Culture, Transfection, and Chemicals. Established human melanoma cell
lines, including 501mel and SK-MEL-28 (available from the American Type
Culture Collection), were grown in Roswell Park Memorial Institute (RPMI)
1640 media (Invitrogen), supplemented with 10% FBS (PAA Laboratories)
and 50 units/mL penicillin, 50 μg/mL streptomycin (Invitrogen). Cell lines of
nonmelanocytic origin, including HeLa and Phoenix-AMPHO, were grown in
Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% FBS
and 50 units/mL penicillin, 50 μg/mL streptomycin. All cells were grown in
humidified incubators at 37 °C with 10% CO2. Cell lines used were authen-
ticated by EUROFINS using short tandem repeat (STR) profiling and myco-
plasma screening conducted monthly.
Osteoclasts were isolated from peripheral blood mononuclear cells iso-
lated from leukocyte cones (National Blood Service) by density gradient
centrifugation. CD14+ monocytes were positively selected using magnetic
beads (Miltenyi) and seeded onto glass coverslips in α-MEM culture media
(without ribonucleosides/deoxyribonucleosides; Lonza) containing 10% FBS,
L-glutamine (2 mM), penicillin (50 IU/mL), and streptomycin sulfate (50 μg/mL).
Cultures were supplemented with macrophage colony-stimulating factor
(M-CSF) (25 ng/mL; R&D Systems) and receptor activator of nuclear factor
kappa B ligand (RANKL) (35 ng/mL; produced in house) every 3 to 4 d. Ma-
ture osteoclasts, considered as multinucleated cells containing ≥3 nuclei,
formed by day 9.
Transient transfection of DNA was carried out using FuGENE 6 (Promega)
according to the manufacturer’s instructions.
HeLa Flp-In T-REx cells were maintained as per WT HeLa cells, but with a
further supplement of 4 μg/mL blasticidin to maintain TetR expression and
50 μg/mL zeocin to ensure that the flippase (Flp) recombination target (FRT)
sites were retained. HeLa Flp-In T-REx cells were cotransfected with the
pcDNA5/FRT/TO plasmid expressing the BRAFV600E under the control of a
tetracycline-regulated CMV/TetO2 promoter, and the pOG44 plasmid that
expresses the Flp recombinase under a constitutive CMV promoter at a
3:1 ratio of pcDNA5/FRT/TO to pOG44. Transfected cells were selected with
200 μg/mL hygromycin and 4 μg/mL blasticidin. Stable polyclonals were ob-
served after 2 wk of antibiotic selection.
Doxycycline, TPA, and LMB were obtained from Sigma-Aldrich, BIO from
Merck, and U0126 and Torin 1 from Cell Signaling Technology.
Expression Vectors and Site-Directed Mutagenesis. MITF-FLAG or MITF-GFP
and derivatives were made by cloning the MITF-M cDNA into p3xFLAG-
CMV-14 (Sigma) or pEGFP-C1 (Clontech). The NES reporter was also con-
structed using pEGFP-C1. BRAFV600E cDNA was inserted into pcDNA5/FRT/TO
(Invitrogen). Point mutations were introduced using the QuikChange
Lightning Site-Directed Mutagenesis (SDM) Kit (Agilent) according to the
manufacturer’s instructions.
Western Blotting. Following SDS/PAGE, proteins were transferred to a Pro-
tran nitrocellulose membrane (Whatman) via electroblotting in transfer
buffer (25 mM Tris, 192 mM glycine, 20% methanol) at 70 V for 90 min.
The membrane was blocked with 5% skimmed milk in 0.1% Tween in PBS
(PBST) for 1 h at room temperature, after which it was incubated with the
primary antibody (typically diluted 1:2,000 in 5% milk in PBST) at 4 °C
overnight with gentle agitation on a rocking platform. The membrane
was then washed three times with PBST for 5 min each time and incubated
with the corresponding horseradish peroxidase (HRP)-conjugated secondary
antibody (Bio-Rad) (diluted 1:5,000 in 5% milk in PBST) for 1 h at room
temperature, before another 3× 5-min wash in PBST. Finally, enhanced
chemiluminescence (ECL) reagent (Amersham) was added, and the signal
was detected with X-ray film (Fujifilm).
Antibodies. Antibodies used were as follows: rabbit anti–β-catenin (ab2365;
Abcam), mouse anti-FLAG (monoclonal M2; Sigma), rabbit anti-ERK (C14;
Santa Cruz), mouse anti-MITF (monoclonal AS9; in house), rabbit anti–
phospho-ERK (Cell Signaling), rabbit anti–phospho-β-catenin (Cell Signal-
ing), anti-CRM1 (Santa Cruz), and anti-RAN (BD Biosciences).
Immunofluorescence and Kinase Inhibitor Screen. Cells were grown to 80%
confluence on glass coverslips (VWR) and fixed with 3.7% paraformaldehyde
(PFA) (Sigma-Aldrich), dissolved in PBS and adjusted to pH 7.4, for 15 min.
After 30 min blocking and permeabilization with 0.1% Triton-X and 1% BSA
in PBS, cells were incubatedwith primary antibody (diluted 1:500 in 1%BSA in
PBST) at 4 °C overnight with gentle agitation on a rocking platform. After
washing three times with PBST for 5 min each time, the cells were incubated
with the appropriate Alexa Fluor-conjugated secondary antibody (Invitrogen)
(diluted 1:1,000 in 1% BSA in PBST) for 1 h, before another 3× 5-min wash in
PBST. DNA was stained with 300 nM 4′,6-diamidino-2-phenylindole (DAPI)
(Invitrogen) in PBS for 15 min, before a 3× 5-min wash in PBST. Coverslips
were mounted on microscope glass slides (VWR) with Vectashield Mounting
Medium (Vector Laboratories) before sealing with nail polish. Images were
acquired using an LSM710 confocal microscope (Carl Zeiss).
For cells expressing fluorescent proteins, cells were stained with DAPI after
PFA fixation. Blocking, permeabilization, and antibody staining steps were
omitted unless detection of nonfluorescent proteins was required. The
coverslips were then mounted and imaged as above.
For the small molecule library screen, ∼5,000 SKmel28 melanoma cells
were seeded into each well of 96-well black CellCarrier plates (PerkinElmer)
with optically clear plastic bottoms. Cells were grown to 80% confluence
overnight, upon which they were treated for 6 h with 2.5 μM of each
compound from the Glaxo Smith Kline (GSK) Published Kinase Inhibitor Set.
Cells were then processed as described in the immunofluorescence protocol.
The quantification of (immuno)fluorescence images was performed using
ImageJ. Nuclear masks were created by DAPI staining, and cytoplasmic masks
by either Phalloidin or Cell Tracker Orange (Thermo Fisher). The percentage
of nuclear MITF intensity was calculated by (MITF in nucleus)/(MITF in whole
cell) × 100% on a per cell basis. Three independent experiments were per-
formed for each quantification with a minimum of 40 cells (****P < 0.0001,
***P < 0.001, **P < 0.01, *P < 0.05, NS, nonsignificant).
SPOT Kinase Assay. Twenty-one-residue-long peptides corresponding to MITF
residues 61 to 81, and incorporating various mutations and modifications,
were immobilized on a cellulose supportmembrane. Themembranewas then
incubated with 100 ng of purified GSK3β kinase (New England Biolabs) and
5 μCi of [γ-32P]-ATP at 30 °C for 30 min. After washing, incorporation of 32P
was detected by phosphorimager. The membrane was imaged in UV light to
show the relative size of the peptide spots.
Bacterial Expression of MITF and in Vitro Phosphorylation. Recombinant 6×
HIS-Tagged MITF (1–100) was expressed in Escherichia coli (Rosetta) by adding
0.1 mM IPTG and incubating overnight at 18 °C. After harvesting, cells were
lysed in a buffer containing 6 M urea, 25 mM Hepes, pH 7.5, 0.5 M NaCl, 5%
glycerol, 20 mM imidazole buffer, pH 7.5, using a French press homogenizer.
After centrifugation of the lysate at 25,000 × g for 15 min, the supernatant
was mixed with Ni-NTA agarose beads (QIAGEN), incubated at 4 °C while
rotating for 1 h, and then placed in a gravity-flow column. Beads were then
washed twice with wash buffer (6 M urea, 25 mM Hepes, pH 7.5, 0.5 M NaCl,
5% glycerol buffer, pH 7.5) and once with lysis buffer before bound protein
was eluted stepwise using imidazole (50 to 250 mM). Purified MITF was visu-
alized by SDS/PAGE and Coomassie staining, and protein-containing fractions


























































were pooled and dialyzed against buffers containing buffers decreasing
concentrations of urea (25 mM Hepes, pH 7.5, 0.5 M NaCl, 5% glycerol, 4.0 to
0.0 M urea) at 4 °C. After dialysis, samples were flash frozen in aliquots in
liquid nitrogen and stored at −80 °C before use.
To phosphorylate MITF in vitro, 2 μg of recombinant HIS-tagged MITF (1–
100) was incubated 1 h at 37 °C with 100 ng of GSK3β (Abcam) and/or ERK2
(Sigma Aldrich) in the presence of cold ATP in a reaction diluted to 22 μL
with kinase dilution buffer (5 mM Mops, pH 7.2, 5 mM MgCl2, 0.4 mM EDTA,
1 mM EGTA, 2.5 mM glycerol 2-phosphate) before adding DTT to a final
concentration of 0.25 mM. When both ERK and GSK3β were used, ERK2 was
used first, and GSK3β was added after 30 min. Reactions were stopped by
addition of 100 mM EDTA.
Proteomics Analysis. Proteins phosphorylated in vitro were subjected to chy-
motrypsin digest (Thermo Fisher) treatment according to the manufacturer’s
instructions, desalted using SepPak reversed phase columns, and injected into
a liquid chromatography-tandem mass spectrometry (LC-MS/MS) platform
(Dionex Ultimate 3000 nano LC and Q-Exactive HF). Sample separation was
undertaken using a 50-cm-long EasySpray column (ES803; Thermo Fisher) with
a 75-μm inner diameter and a gradient of 2 to 35% acetonitrile in 0.1% formic
acid and 5%DMSOwith a 250 nL/min flow rate for 60 min. MS1 spectra with a
resolution of 60,000 and an ion target of 3 million were acquired for a
maximum of 45 ms. MS/MS data were acquired after isolation with a mass
window of 1.2 Th and fragmentation at 28% normalized collision energy
(higher-energy collisional dissociation, resolution 30,000). PEAKS Server V.8.5
(Bioinformatics Solutions) and a Uniprot/Trembl database were used to ana-
lyze the LC-MS/MS data set to identify phosphorylation (S, T, Y), as well as
oxidation (M) and deamidation (N, Q). Mass tolerance was 10 ppm for pre-
cursor and 0.5 Da for fragment mass, with a peptide level false discovery rate
set to 1%. Freestyle 1.3 (Thermo Fisher) was used to generate extracted ion
chromatograms of relevant peptides that were quantified after Gaussian
smoothing (three data points).
MITF-CRM1 Interaction Assay. N-terminally GST-tagged CRM1 was expressed
in E. coli after induction overnight at 18 °C with 0.5 mM isopropyl-β-D-
thiogalactopyranoside (IPTG) and purified at 4 °C using glutathione beads
from extracts of sonicated bacteria that had been precleared by centrifu-
gation at 50,000 × g for 30 min at room temperature. Purified protein was
released from the beads by cleavage using TEV protease. Recombinant
CRM1 was then further purified using a MonoQ HP column and eluted using
a 0 to 1 M NaCl gradient in a buffer containing 20 mM Tris (pH 7.5, 1 mM
EGTA, 2 mM MgAc, 1 mM DTT, and 10% glycerol). Human HIS-tagged RAN
protein was similarly expressed in E. coli but was purified by affinity chro-
matography on Ni-NTA beads. Bound RAN was eluted using 500 mM imid-
azole and subsequently purified using a Superdex-75 column (Amersham
Biosciences) in 20 mM Tris (pH 8.0), 1 mM DTT, 10% (vol/vol) glycerol. To
obtain a GTP-bound fraction, purified Ran was incubated with GTP at a 1,000-
molar excess in 50 mM Hepes, pH 7.5, 10 mM EDTA, 4 mM DTT, 2 mM ATP at
30 °C for 30 min, before the reaction was halted using 15 mM MgCl2 at 4 °C.
HIS-tagged amino acids 1 to 105 of the MITF-M isoform expressed in E. coli
cells were expressed as described for RAN. After sonication in denaturing lysis
buffer [50 mM Hepes, pH 7.5, 500 mM NaCl, 20 mM imidazole, 5% (vol/vol)
glycerol, 10 mM β-mercaptoethanol, 6 M urea], MITF protein was isolated by
direct binding to Ni-NTA beads. The beads were then washed extensively, and
bound protein was refolded by stepwise decreasing the urea concentration
from 6 M to 0 M using volumes of 10 mL and a 1 mL/min flow rate. Then,
100 pmol of MITF protein bound to Ni-NTA beads was used together with
50 pmol CRM1 with or without a twofold molar excess of GTP-bound Ran.
Proteins were mixed in 400 μL binding buffer comprising 20 mM Hepes (pH 7.5),
2 mMmagnesium acetate, 110mMpotassium acetate, 1 mM EGTA, 20mMDTT,
0.005% Nonidet P-40, and 20 mM imidazole and rotated for 2 h at 4 °C. Beads
were washed four times with binding buffer to remove unbound protein before
addition of hot Laemmli buffer. Protein complexes were analyzed by SDS/PAGE,
and CRM1 and RAN were detected by Western blotting.
Zebrafish. Two nanoliters of plasmid DNA containing the zebrafishmitfa gene
promoter (62) drivingWT and mutant fish MITF cDNA (25 ng/μL) together with
Tol2 mRNA (35 ng/μL) was injected into mitfa-null nacre embryos at the one-
cell stage and grown at 28.5 °C for 5 d. Embryos were then exposed briefly to
white light to contract melanocytes and subsequently imaged before fixation
in 4% PFA. The surface melanocytes in the head, trunk, and yolk sac were then
counted. Quantitative analysis of melanocyte development in groups of fish
injected with different mutant forms of MITF was carried out with the Minicab
16 statistical software (Minitab Inc). One-way ANOVA was used to determine
the difference between two groups. For imaging expression of Mitfa,
VC7 embryos (62) were grown for 24 h postinjection and processed for
immunostaining using anti-FLAG antibody (F7425, rabbit 1:150; Sigma) and
rabbit Alexa Fluor 488-conjugated secondary antibody (1:250) before visuali-
zation using a Leica confocal SP5 microscope at 10× magnification. For
quantification of mitfa gene expression at 24 hours postfertilization by RT-
PCR, nacre mutant fish have a point mutation C > T at position 337 in the
Mitfa ORF, resulting in a premature TAA stop codon and truncated Mitfa
protein. To distinguish transgenicmitfa from endogenous nacremitfa, the last
G nucleotide at the 3′ end of the reverse primer differs betweenWT and nacre
so as not to amplify the mutant allele. The sequences ofmitfa primers used for
both RT-PCR and q-PCR are as follows: mitfa-F, 5′-CGCCGAGCACGGCATGACC-
3′; and mitfa-WT-R, 5′-TGAAACTGGAATCGTGTTTGTCATTTG-3′. The size of
product is 193 bp. Zebrafish β-actin was used as an internal control. The primer
sequences for β-actin are as follows: actin-F, 5′-TGCCATGTATGTGGCCATCCA-
3′; actin-R, 5′-ACCTCCAGACAGCACTGTGT-3′ with an amplicon of 602 bp; if
there is genomic DNA contamination, an additional amplicon of 689 bp will be
seen. For reproducibility, the Zebrafish experiments were repeated three times
and were approved by the University of Edinburgh Animal Welfare and Ethical
Review Body and undertaken in accordance with the Animals (Scientific Pro-
cedures) Act 1986. Zebrafish lines were bred, raised, and maintained as de-
scribed (63).
Subcellular Fractionation. To separate out the cytosolic components of the cell
from the nuclear fraction, trypsinized cells were lysed in cold Triton X lysis
buffer (50 mM Tris-Cl, pH 7.5, 137.5 mM NaCl, 0.5% Triton X-100, 10%
glycerol) supplemented with 1× Complete Protease Inhibitor and 1× Phos-
STOP Phosphatase Inhibitor. The cell lysate was incubated on ice for 20 min
and then centrifuged at 16,000 × g and 4 °C in a bench-top centrifuge for
15 min. The supernatant was the cytoplasmic fraction while the pellet was
resuspended in 1× Laemmli sample buffer and taken to be the nuclear
fraction. Both fractions were stored at −20 °C.
Luciferase Reporter Assay. Cells were plated overnight in 24-well plates
(Corning) until 50% confluent and then transfected with two plasmids in a
1:1 ratio: a plasmid encoding MITF and a plasmid encoding the firefly lu-
ciferase gene under the control of the TYR promoter. Cells were harvested
48 h posttransfection by incubating with 100 μL of Passive Lysis Buffer
(Promega) for 30 min at 4 °C on a rocking platform. Then, 20 μL of the lysate
was mixed with 50 μL of Luciferase Assay Reagent (Promega) in a white 96-
well plate (Corning), after which luminescence was detected with a GloMax-
Multi Microplate Multimode Reader (Promega) luminometer.
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